Khairy Paul, Harris Louise, Landzberg Michael J, Viswanathan Sangeetha, Barlow Amanda, Gatzoulis Michael A, Fernandes Susan M, Beauchesne Luc, Therrien Judith, Chetaille Philippe, Gordon Elaine, Vonder Muhll Isabelle, Cecchin Frank
Adult Congenital Heart Center, Montreal Heart Institute, 5000 Bélanger St, Montreal, Quebec, Canada H1T 1C8.
Circulation. 2008 Jan 22;117(3):363-70. doi: 10.1161/CIRCULATIONAHA.107.726372. Epub 2008 Jan 2.
Tetralogy of Fallot is the most common form of congenital heart disease in implantable cardioverter-defibrillator (ICD) recipients, yet little is known about the value of ICDs in this patient population.
We conducted a multicenter cohort study in high-risk patients with Tetralogy of Fallot to determine actuarial rates of ICD discharges, identify risk factors, and characterize ICD-related complications. A total of 121 patients (median age 33.3 years; 59.5% male) were enrolled from 11 sites and followed up for a median of 3.7 years. ICDs were implanted for primary prevention in 68 patients (56.2%) and for secondary prevention in 53 (43.8%), defined by clinical sustained ventricular tachyarrhythmia or resuscitated sudden death. Overall, 37 patients (30.6%) received at least 1 appropriate and effective ICD discharge, with a median ventricular tachyarrhythmia rate of 213 bpm. Annual actuarial rates of appropriate ICD shocks were 7.7% and 9.8% in primary and secondary prevention, respectively (P=0.11). A higher left ventricular end-diastolic pressure (hazard ratio 1.3 per mm Hg, P=0.004) and nonsustained ventricular tachycardia (hazard ratio 3.7, P=0.023) independently predicted appropriate ICD shocks in primary prevention. Inappropriate shocks occurred in 5.8% of patients yearly. Additionally, 36 patients (29.8%) experienced complications, of which 6 (5.0%) were acute, 25 (20.7%) were late lead-related, and 7 (5.8%) were late generator-related complications. Nine patients died during follow-up, which corresponds to an actuarial annual mortality rate of 2.2%, which did not differ between the primary and secondary prevention groups.
Patients with tetralogy of Fallot and ICDs for primary and secondary prevention experience high rates of appropriate and effective shocks; however, inappropriate shocks and late lead-related complications are common.
法洛四联症是植入式心脏转复除颤器(ICD)植入患者中最常见的先天性心脏病类型,但对于ICD在该患者群体中的价值知之甚少。
我们对高危法洛四联症患者进行了一项多中心队列研究,以确定ICD放电的精算率,识别风险因素,并描述与ICD相关的并发症。总共121例患者(中位年龄33.3岁;59.5%为男性)从11个地点入组,中位随访3.7年。68例患者(56.2%)植入ICD用于一级预防,53例(43.8%)用于二级预防,二级预防的定义为临床持续性室性快速心律失常或复苏的心脏性猝死。总体而言,37例患者(30.6%)接受了至少1次适当且有效的ICD放电,室性快速心律失常的中位心率为213次/分钟。一级预防和二级预防中适当ICD电击的年精算率分别为7.7%和9.8%(P=0.11)。较高的左心室舒张末期压力(每毫米汞柱风险比1.3,P=0.004)和非持续性室性心动过速(风险比3.7,P=0.023)在一级预防中独立预测适当的ICD电击。每年有5.8%的患者发生不适当电击。此外,36例患者(29.8%)出现并发症,其中6例(5.0%)为急性并发症,25例(20.7%)为晚期导线相关并发症,7例(5.8%)为晚期发生器相关并发症。9例患者在随访期间死亡,对应年精算死亡率为2.2%,一级预防组和二级预防组之间无差异。
接受一级和二级预防ICD治疗的法洛四联症患者经历适当且有效电击的比例较高;然而,不适当电击和晚期导线相关并发症很常见。